Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | PRMT3 | O60678 | 7/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19860042 | 0.89 | MEN1 (0.60) | LMNAHPGDKDM4EALDH1A1PRMT3 | |
| SCHEMBL19860124 | 0.86 | IMPDH2 (0.59) | KDM4EALDH1A1PRMT3IMPDH2NOTUM | |
| SCHEMBL14124377 | 0.85 | PRMT3 (0.51) | LMNAHPGDKDM4EALDH1A1PRMT3 | |
| SCHEMBL19860106 | 0.84 | ROCK1 (0.57) | PRMT3IMPDH2NOTUMMEN1KMT2A | |
| SCHEMBL2162616 | 0.84 | IMPDH2 (0.70) | KDM4EALDH1A1PRMT3IMPDH2NOTUM | |
| SCHEMBL2162395 | 0.82 | ROCK2 (0.61) | KDM4EPRMT3IMPDH2NOTUMNAMPT | |
| SCHEMBL19860110 | 0.81 | IMPDH2 (0.59) | PRMT3IMPDH2NOTUMROCK2 | |
| SCHEMBL19860120 | 0.81 | PRMT3 (0.53) | HPGDKDM4EALDH1A1PRMT3IMPDH2 | |
| SCHEMBL19860105 | 0.79 | PRMT3 (0.62) | PRMT3IMPDH2NOTUM | |
| SCHEMBL22751984 | 0.79 | ROCK2 (0.53) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455513-B2 | Kinase inhibitors; anticarcinogenic agents; obesity, glaucoma; N-(4-(3-(isoquinolin-6-ylamino)-3-oxopropyl)phenyl)-4-methoxybenzamide | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2008086269-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | LMNA 2665/4885HPGD 1195/4885KDM4E 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.